RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases - PubMed (original) (raw)
Comparative Study
doi: 10.1038/ng1021. Epub 2002 Nov 4.
Phillippa J Neville, Sarah J Plummer, Ying Xiang, Lisa M Krumroy, Eric A Klein, William J Catalona, Nina Nupponen, John D Carpten, Jeffrey M Trent, Robert H Silverman, John S Witte
Affiliations
- PMID: 12415269
- DOI: 10.1038/ng1021
Comparative Study
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
Graham Casey et al. Nat Genet. 2002 Dec.
Abstract
RNASEL (encoding ribonuclease L) has recently been proposed as a candidate for the hereditary prostate cancer (HPC1) gene. We determined that the RNASEL variant Arg462Gln has three times less enzymatic activity than the wildtype and is significantly associated with prostate cancer risk (P = 0.007). At least one copy of the mutated allele that causes this substitution is carried by nearly 60% of the men in our study. Men that are heterozygous with respect to the mutated allele have 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the risk.
Comment in
- RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.
Walsh PC. Walsh PC. J Urol. 2003 Apr;169(4):1591. J Urol. 2003. PMID: 12641088 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases